Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia

Sergio D Bergese, Sonia Ramamoorthy, Gary Patou, Kenneth Bramlett, Stephen R Gorfine, Keith A Candiotti, Sergio D Bergese, Sonia Ramamoorthy, Gary Patou, Kenneth Bramlett, Stephen R Gorfine, Keith A Candiotti

Abstract

Background: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration.

Methods: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75-200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery.

Results: Overall, 45% of patients were male and 19% were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated.

Conclusion: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries.

Keywords: analgesic; local anesthetic; pain; postsurgical; wound infiltration.

Figures

Figure 1
Figure 1
Cumulative pain score (AUC0–24 of NRS). Notes: Differences in AUC for pain at rest from 0 to 24 hours between liposome bupivacaine and control groups. Circles represent the difference in means, and bars represent the 95% confidence intervals for the difference in means. The perpendicular zero line indicates no difference between liposome bupivacaine and controls. If a confidence interval does not cross the zero line, there is a statistically significant difference (P < 0.05) between liposome bupivacaine and controls. Abbreviations: AUC, area under the curve; HCI, hydrochloride; NRS, numeric rating scale; TKA, total knee arthroplasty.
Figure 2
Figure 2
Cumulative pain score (AUC0–72 of NRS). Notes: Differences in AUC for pain at rest from 0 to 72 hours between liposome bupivacaine and control groups. Circles represent the difference in means and bars represent the 95% confidence intervals for the difference in means. The perpendicular zero line indicates no difference between liposome bupivacaine and controls. If a confidence interval does not cross the zero line, there is a statistically significant difference (P < 0.05) between liposome bupivacaine and controls. Abbreviations: AUC, area under the curve; HCI, hydrochloride; NRS, numeric rating scale; TKA, total knee arthroplasty.

References

    1. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003;97(2):534–540.
    1. Warfield CA, Kahn CH. Acute pain management. Programs in US hospitals and experiences and attitudes among US adults. Anesthesiology. 1995;83(5):1090–1094.
    1. Beauregard L, Pomp A, Choiniere M. Severity and impact of pain after day-surgery. Can J Anaesth. 1998;45(4):304–311.
    1. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116(2):248–273.
    1. White PF. Multimodal analgesia: its role in preventing postoperative pain. Curr Opin Investig Drugs. 2008;9(1):76–82.
    1. Jirasiritham S, Tantivitayatan K, Jirasiritham S. Perianal blockage with 0.5% bupivacaine for postoperative pain relief in hemorrhoidectomy. J Med Assoc Thai. 2004;87(6):660–664.
    1. Chester JF, Stanford BJ, Gazet JC. Analgesic benefit of locally injected bupivacaine after hemorrhoidectomy. Dis Colon Rectum. 1990;33(6):487–489.
    1. Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology. 2002;96(3):725–741.
    1. Moiniche S, Mikkelsen S, Wetterslev J, Dahl JB. A qualitative systematic review of incisional local anaesthesia for postoperative pain relief after abdominal operations. Br J Anaesth. 1998;81(3):377–383.
    1. Yoost TR, McIntyre M, Savage SJ. Continuous infusion of local anesthetic decreases narcotic use and length of hospitalization after laparoscopic renal surgery. J Endourol. 2009;23(4):623–626.
    1. Mahabir RC, Peterson BD, Williamson JS, Valnicek SM, Williamson DG, East WE. Locally administered ketorolac and bupivacaine for control of postoperative pain in breast augmentation patients. Plast Reconstr Surg. 2004;114(7):1910–1916.
    1. Wheatley GH, III, Rosenbaum DH, Paul MC, et al. Improved pain management outcomes with continuous infusion of a local anesthetic after thoracotomy. J Thorac Cardiovasc Surg. 2005;130(2):464–468.
    1. International Conference on Harmonisation Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; June 10, 1996; Washington DC. [Accessed March 1, 2011]. Available at: .
    1. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. [Accessed April 26, 2010]. Available at: .
    1. Bramlett KW, Jones RK, Pink M, Pink T. A single administration of DepoBupivacaine intraoperatively provides analgesia and reduction in use of rescue opiates compared to bupivacaine HCl in patients undergoing total knee arthroplasty [Abstract 0278]. Presented at the XXXVI Biennial World Congress of the International College of Surgeons; December 3–6, 2008; Vienna, Austria.
    1. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28(9):776–788.
    1. Gorfine S, Krivokapic Z. Extended-release multivesicular liposome bupivacaine (Exparel™) is superior to placebo for posthemorrhoidectomy pain reduction [Abstract P230] Dis Colon Rectum. 2011;54(5):174.
    1. Langford RM, Chappell GM, Karrasch JA. A single administration of DepoBupivacaine intraoperatively results in prolonged detectable plasma bupivacaine and analgesia in patients undergoing inguinal hernia repair [Abstract P-9088]. Presented at the Annual Postgraduate Assembly in Anesthesiology of the New York State Society of Anesthesiologists; December 12–16, 2008; New York, NY.
    1. Miller H, Terem TM, Kheladze K, Mosidze B. A single administration of DepoBupivacaine intraoperatively provides three-day analgesia and reduction in use of rescue opioids in patients undergoing hemorrhoidectomy [Abstract]. Presented at the Annual Meeting of the American Society of Colon and Rectal Surgeons; May 2–6, 2009; Hollywood, FL.
    1. Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam® bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammoplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012;32(1):69–76.
    1. White PF, Schooley GL, Ardeleanu M. Analgesia following a single administration of depobupivacaine intraoperatively in patients undergoing inguinal herniorrhaphy: preliminary dose-ranging studies [Abstract S-242] Anesth Analg. 2009;108(Suppl 3S):S242.
    1. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbard LE, Molinoff PB, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться